Tocilizumab for the Treatment of Refractory Behcet's Uveitis

Sponsor
Wenjie Zheng
Study ID
NCT03554161
Phase
PHASE2
Status
Terminated

Conditions

  • Behcet Syndrome
  • Uveitis

Eligibility Criteria

Sex
ALL
Age
18 Years - 65 Years
Healthy Volunteers
Not accepted

Interventions

  • Tocilizumab (TCZ) — BIOLOGICAL
    Patients with refractory BD associated uveitis will receive Tocilizumab therapy, the efficacy and corticosteroids-tapering effects will be evaluated.

Study Details

The aim of this single-center prospective study is to evaluate the efficacy and safety of Tocilizumab (TCZ), humanized monoclonal antibody against IL-6receptor, in the treatment of refractory Uveitis of Behçet's disease (BDU), to verify its effects on decreasing the dose of cortical steroids, and to determine whether it can reduce BDU recurrence.

Key Dates

Start date
May 10, 2018
Status verified
Mar 2021
Primary completion
Feb 1, 2021
Completion
Feb 1, 2021

Study Design

Enrollment
3 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Tocilizumab for refractory BDU
    This study is a self-control study and all the participants will be enrolled in the interventional arm.

Primary Outcome Measure

Efficacy of Tocilizumab on BD Uveitis [ Time Frame: four weeks ]

Related Studies